Phase 2 Study for C3G and MPGN patients
A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
This study will determine the effectiveness of a compound called ACH-0144471 at improving the clinical symptoms of C3G of IC-MPGN
Trial Physician / Study Coordinator
Clinical Trial Team
Email Phone 203-752-5566Site Name
University of Alabama
Phase 2 Study for C3G and MPGN patients
A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
This study will determine the effectiveness of a compound called ACH-0144471 at improving the clinical symptoms of C3G of IC-MPGN
Eligibility Criteria
Patient Population
C3 Glomerulonephritis / C3 Glomerulopathy (C3G) or Immune Complex Membranoproliferative Glomerulonephritis
(IC-MPGN)
About the Drug
What is involved for the patient
Patients will participate for 1 year. Additional study visits and diagnostic tests may be required, including biopsies and labwork.
Sponsor
Achillion Pharmaceuticals
Target Enrollment
20
Estimated End Date
May, 2020
About the Trial
Study Drug
ACH-0144471
Study Goal
This study will look at the whether the study drug is improving symptoms through a renal biopsy.
About the drug or intervention
ACH-0144471 is an oral tablet that study participants will take daily.